Toshihiko Nishimura

US Patent:

7628768, Dec 8, 2009

Filed:

Oct 7, 2004

Appl. No.:

10/961731

Inventors:

John L. Faul - Stanford CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter N. Kao - Palo Alto CA, US
Ronald G. Pearl - Palo Alto CA, US

Assignee:

Rox Medical, Inc. - San Clemente CA

International Classification:

A61M 19/00

US Classification:

604 8, 604264

Abstract:

A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml/min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.

US Patent:

8048016, Nov 1, 2011

Filed:

Feb 12, 2009

Appl. No.:

12/378438

Inventors:

John L. Faul - Stanford CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter N. Kao - Palo Alto CA, US
Ronald G. Pearl - Palo Alto CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Stanford CA

International Classification:

A61M 19/00

US Classification:

604 8, 604264

Abstract:

A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml/min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.

US Patent:

20040249335, Dec 9, 2004

Filed:

Apr 6, 2004

Appl. No.:

10/820169

Inventors:

John Faul - Stanford CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter Kao - Palo Alto CA, US
Ronald Pearl - Palo Alto CA, US

International Classification:

A61F002/06

US Classification:

604/009000, 623/001240

Abstract:

A long-term implantable arteriovenous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml/min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.

US Patent:

20050119330, Jun 2, 2005

Filed:

Mar 15, 2004

Appl. No.:

10/801729

Inventors:

Peter Kao - Palo Alto CA, US
Ronald Pearl - Palo Alto CA, US
Toshihiko Nishimura - Menlo Park CA, US
John Faul - Stanford CA, US

International Classification:

A61K031/401
A61K031/366
A61K031/255

US Classification:

514423000, 514460000, 514548000

Abstract:

Methods of treating lung proliferative vascular disorders by administering an antiproliferative agent are provided. A preferred antiproliferative agent is a HMG-CoA reductase inhibitor, preferably simvastatin. Vascular occlusion in the pulmonary arteries of the patient is reduced as a result of the treatment through a reduction in neointimal hyperplasia and medial hypertrophy, and the restoration of normal endothelial cell function. The treatment also results in a reversal of right side cardiac hypertrophy. Lung proliferative vascular disorders that can be treated include primary pulmonary hypertension, secondary pulmonary hypertension, Eisenmenger's syndrome, chronic thromboembolic disease, pulmonary fibrosis, obliterative bronchiolitis, or lymphangioleiomyomatosis. Dosages and pharmaceutical formulations are provided.